Biotech & Healthcare

Breast Cancer Novel Therapeutics Firm Atossa Genetics Will Be Presenting at LD Micro Main Event Conference on Tuesday Dec 10 In LA

Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presenter at the LD Micro Main Event on December 10, 2019, at 12:...

Seattle Genetics & Astellas Enter An Agreement With Merck To Assess Effectiveness Of Drug For Metastatic Urothelial Cancer

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the le...

Aslan Skyrockets (+36.13%), NeuBase Therapeutics Pops (+8%), Hecla Bumps (+2.43%) & Market/Manufacturing Drops – Vista Partners Daily Market Recap 12/2/19

The broad markets dropped this first trading day in December in a reaction to the ISM Manufacturing Index report for November which confirmed a 48.1% reading vs. a 48.3% reading for October still south of the Mendoza line for expansion and this did nothing to excite the market. The S&P 500 real...

United Health Foundation & The Colorado Center For Nursing Excellence Seeking To Produce Better Behavioral Health Clinical Practice

Reportedly, The United Health Foundation is initiating a $1.5 million grant to the Colorado Center for the next three-years. This will go to support and recruit 39 currently-employed rural Advanced Practice Registered Nurse Behavioral Health Fellows. The move will further go to help the fellows to r...

Tech Data Leaps (+12.32%) On Apollo Bid & Broad Markets Take It On Chin! Vista Partners Daily Market Recap 11/29/19

Big Movers Shares of Tech Data (TECD) lept +12.32% today closing at $144.89/share. Private equity firm Apollo Global Management agreed to pay $145/share for TECD on Wednesday, up from its original bid of $130/share of Warren Buffett's Berkshire bid of $140/share from last week. TECD op...

Unexpected Key Data Points, AVX Corp (+18.97%), INVO Bioscience (+9.09%) & Broad Markets Rise! Vista Partners Daily Market Recap 11/27/19

Big Movers Shares of AVX Corporation (AVX) jumped +36.37% today. AVX is a leading manufacturer and supplier of advanced electronic components and interconnect, sensor, control, and antenna solutions that yesterday won the South Carolina Life Sciences Pinnacle Award for Organizational Con...

The Latest on Gene Silencing Biotech Firm Arrowhead Pharmaceuticals Fiscal Year 2019 Results

Recently, Arrowhead Pharmaceuticals (ARWR), a company that develops medicines that treat intractable diseases by silencing genes that cause them, announced its earnings report for the quarter ending September 30, 2019. The company hosted a live webcast of the event, a replay of which will be availab...

Arrowhead Pharma, Nutanix, Retail Sector & Broad Markets Rise! Vista Partners Daily Market Recap 11/26/19

Big Movers Arrowhead Pharmaceuticals, Inc. (ARWR), a company that develops medicines that treat intractable diseases by silencing the genes that cause them rose +18.79% today closing at $67.70/share. Yesterday after the close the company hosted the fiscal year 2019 conference call to revi...

The Medicines Company (MDCO), IBB, & Russell 2000 Post Big Wins! Vista Partners Daily Market Recap 11/25/19

Big Movers Novartis (NVS) announced that it is buying The Medicines Company (MDCO) and its experimental treatment inclisiran uses a new approach to lower bad cholesterol in especially hard to treat patients for $9.7B. Shares of MDCO jumped +22.25% closing at $83.80/share. The Ishares N...

Select Walgreens Stores To Launch UnitedHealthcare’s Member Medicare Services Centers

Reportedly, UnitedHealthcare and Walgreens are set to launch 14 UnitedHealthcare Medicare services centers within Walgreen stores in Las Vegas, Phoenix, Cleveland, Denver, and Memphis markets in January 2020. The initiative which is part of a multiyear agreement between the companies will allow Walg...

“Friday Market Drifts Up, Nordstrom & Buffett’s StoneCo Ltd. Surge!” Vista Partners Daily Market Recap 11/22/19

Big Movers Nordstrom (JWM) soared to $37.95/share up +10.58% today after beating Wall Street's expectations as they saw their digital sales drive Q3 performance leading them to revise their guidance upward. A leading provider of financial technology solutions that empower merchants to ...

“TD Ameritrade Flys On Chuck Schwab Interest” Vista Partners Daily Market Recap 11/21/19

Big Movers According to a plethora of sources, today Charles ("Chuck") Schwab (SCHW) is making a move to combine with rival brokerage firm TD Ameritrade (AMTD), a deal that could be worth more than $25B. It would also create a new behemoth company in the brokerage space with over $5T in c...

Will Novartis Acquire Parsippany-based The Medicines Company?

Reportedly, Novartis AG is in talks to acquire Parsippany, New Jersey-based The Medicines Company (MDCO) a developer of a promising cholesterol drug, as per sources. Other potential acquirers have also shown interest in the purchase of Medicines, tripling the value of its shares recently this year ...

“No Phase One In 2019? – Target & Neubase Therapeutics Jump!” Vista Partners Daily Market Recap 11/20/19

Big Movers Target Corporation (TGT) jumped +14.06% closing at $126.43/share after crushing earnings expectations and reporting a surge of +4.5% in same-store sales in Q3. Vista Partners recently highlighted a "one-to-watch-stock" in the weekly market recap called Neubase Therapeutics (...

New Type of IVF Treatment From Newcomer INVO Bioscience Is Headed To Reno

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. With this in mind, the business, art, & the science of gettin...

INVO Bioscience, Developers Of The World’s Only In Vivo FDA Cleared Intravaginal Culture System, Will Host A Live Investor Webcast at 11:00 AM ET (8:00 am PT) on Thursday, November 21, 2019

 The business, art, & the science of getting pregnant in today's world is receiving greater focus from venture capitalists, private equity firms, mutual funds, and family offices. This interest is evidenced in the increasing number of startups innovating in the fertility space in recent years a...

Merck Acquires (Developer Of Selective Small Molecule Agonists to TRPML1) Calporta Therapeutics

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the le...

INVO Bioscience, Developers of INVOcell® (The World’s Only In Vivo Intravaginal Culture System), Reports Q3 Progress

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. The INVOcell system (pictured above) is a novel fertility t...

Breast Cancer Treatment Developer Atossa Genetics Announced Recent Q3 Developments & Upcoming Significant Q4 2019 Milestones

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the third quarter ended September 30, 2019, and provides an update on recent co...

Google Enters Agreement With Ascension, The Largest Catholic Health System In The World

Reportedly, Google (GOOG) has entered an agreement with Ascension, its biggest cloud-computing customer in healthcare to date. Ascension, having operations over 150 hospitals across the United States is expected to move some data and analytics tools in its facilities to Google's servers. The deal wi...

INVO Bioscience Enters New Commercialization Agreements For INVOcell®, The World’s Only In Vivo Intravaginal Culture System, In Eurasia (Turkey & Jordan)

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the estimated 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. The INVOcell system (pictured above) is a novel fertility tre...

UnitedHealth Group Appoints Sir Andrew Witty As President

As per reports, Andrew Witty has been appointed as the President for the UnitedHealth Group. Witty is now set to manage enterprise business strategy formulation and development, as president in addition to his responsibilities as Optum CEO. Witty was formerly named as the executive vice president...

New Commercialization Partners’ Agreements Support INVO Bioscience’s Planned Worldwide Rollout of INVOcell – The World’s Only In Vivo Intravaginal Culture System

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the 150 million infertile couples worldwide are treated, with the primary prohibiting factor being cost and access to treatment. INVO Bioscience's (IVOB) INVOcell system is a novel fertility treatment tha...

“Pause” Vista Partners Daily Market Recap 11/6/19

Wednesday, November 6th seemed to produce a time that most were pausing as the markets were basically flat.  The markets' recent runup into record territory called for this to happen and of course, we had to deal with yet another turn of understanding with regard to the trade wars too as st...

Parents Magazine Recognizes INVO Bioscience Pioneers of World’s Only In Vivo Intravaginal Culture System – INVOcell

Parents magazine, a leading publication devoted to parenting from pregnancy to the school years, announced in its recent issue that the Center for Assisted Reproduction in Bedford and Fort Worth, Texas, owned by Drs. Kevin and Kathy Doody have been judged to be one of the 10 Best Fertility Clinics f...

“Holy Biotech Batman! (NXTC +248.92%, $2.09B Mkt Cap)” Vista Partners Daily Market Recap 11/5/19

Tuesday, November 5th brought forth a reminder of why I continue to invest in the biotech space as NextCure, Inc. (NXTC) jumped an amazing +248.92% closing at $92.22/share after reaching $109/share. NXTC traded 7.88 million shares and now enjoys a 2.09B market cap. NXTC opened trading at $25...

“Phase 1 Today” Vista Partners Daily Market Recap 11/4/19

Monday, November 4th brought our attention again towards stories regarding the US-China trade wars. Specifically that we should have confidence that a phase 1 agreement is still on track for this year between these two super economic powers. US Commerce Secretary Wilbur Ross shared that he ...

“Smashing” Vista Partners Daily Market Recap 11/1/19

We welcomed our first day of November with the October jobs report surfacing and smashing expectations. The unemployment is now at a 5-decade low while wages were confirmed to have increased a bit. This was indeed enough to give the markets the much-needed fuel to move higher. As a result, ...

“Happy Halloween” Vista Partners Daily Market Recap 10/31/19

Happy Halloween! Well, as the lead picture in this story might indicate it was not so happy of a day for market participants today as the markets sold off for the most part as concerns around the US-China trade wars surfaced its scary head again.  Reports that officials in China having doub...

Please Read Alternative Infertility Treatments Firm INVO Bioscience, Inc.’s (IVOB) New CEO Letter To Shareholders

Today INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of the FDA cleared INVOcell®, the world's only in vivo Intravaginal Culture System, published a letter to shareholders written by its newly ...

Pfizer Strong Sales of Cancer Drug Ibrance In Q3 – Raises 2019 Forecast

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

“Third Time Is A Charm?” Vista Partners Daily Market Recap 10/30/19

It would seem that the Fed's move today to cut interest rates by another quarter-point for the third time this year was indeed a charm as the markets continued moving upward for the most part. The benchmark interest rate is now in a target range of 1.5% to 1.75%. The fed stated that the move...

Merck Records High Q3 Profits, Beat Estimates

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the le...

“Waiting…” Vista Partners Daily Market Recap 10/29/19

As we await the Fed's Wednesday decision to lower interest rates again for the third time this year,  the S&P 500 hit an all-time new high prior to ending today's session down by 2.53 points or -.08% as it closed at 3,036.89. Firms making up just over 50% of the S&P 500’s market ...

Hits & Misses From Walgreens Q4 Report Plus Jenny Craig Relationship

Walgreen Boots Alliance (WBA), a relatively recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Walgreens Boots Alliance’s reported its fiscal Q4 prof...

“Looking Probably Ahead” Vista Partners Daily Market Recap 10/28/19

The markets today seemed to be reacting to a number of actions at the macro level that once again buoyed the markets into positive and record territory. Today, according to a Reuters article,  one of those factors played a hand we heard from President Trump regarding the US_-China trade war...

“Positive Sentiment” Vista Partners Daily Market Recap 10/25/19

At the end of the day, the results of the market rose strongly on the sentiment that the US-China trades were heading towards a positive outcome as we head into next week's likely interest rate cut as the Fed makes its decision on Wednesday.  The S&P 500 ended today's session up by 12.2...

Breast Cancer Focused Atossa Genetics Is Presenting At Dawson James Small Cap Growth Conference In Jupiter Oct. 29th

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that Kyle Guse, CFO and General Counsel of Atossa Genetics will be a featured presenter at the 5th...

“Microsoft, Dow, Paypal, INVO Bioscience, & Tesla Jump Today” Vista Partners Daily Market Recap 10/24/19

Shares of Microsoft (MSFT), Dow (DOW), Paypal (PYPL), INVO Bioscience (IVOB) & Tesla (TSLA) all jumped today.  Microsoft released Q3 earnings after the close yesterday beating expectations as cloud services boosted revenue and ended today's trading at $139.94/share up 1.97%. Dow (DOW) ...

INVO Bioscience Gains EU CE Mark For World’s Only In Vivo Intravaginal Culture System

Worldwide, the fertility treatment market is severely underserved. Currently, only 1% to 2% of the 150 million infertile couples worldwide are treated, or approximately 1.5 million IVF cycles annually, with the primary prohibiting factor being cost and access to treatment. The INVOcell solution, whi...

“Moderately Green Session” Vista Partners Daily Market Recap 10/23/19

A number of companies from the S&P 500 & Dow 30 continued to report their Q3 earnings again today with varying degrees of success or failures to meet Wall Street's expectations, but at the end of the day, the markets ended in moderately green territory. Of note, Boeing (BA) reported ...

Positive Topline Results For Seattle Genetics’ Metastatic HER2-Positive Breast Cancer Study

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. An estimated 271,270 new cases of invasive breast cancer will be diagnosed in the U.S. in 2019.1 Between 1...

“Earnings & Brexit” Vista Partners Daily Market Recap 10/22/19

A number of companies from the S&P 500 & Dow 30 continued to report their Q3 earnings today while the Brexit reared its ugly head towards the end of the day to put a damper on any excitement that was bubbling early in the markets. Procter & Gamble (PG) beat expectations, United T...

NBA Champion Michael Jordan Funding Healthcare Clinics In Charlotte

Last week, Michael Jordan, a six-time NBA champion and owner of Charlotte Hornets unveiled its first out of two medical clinics in the North Carolina city. The clinics which are strategically placed in areas in need of quality medical care will offer health-care services to Charlotte residents, incl...

“Apple Leads Market” Vista Partners Daily Market Recap 10/21/19

Apple (AAPL) hit a new high as Raymond James updated its AAPL price target from $225 to $280 today which in turn led the market forward. AAPL shares closed at $240.51/share after hitting a new all-time high of $240.99 a touch higher. At the end of the day, the S&P 500 ended today's se...

“Heavy Friday” Vista Partners Daily Market Recap 10/18/19

The market traded in the red today as a few issues were feeling a bit heavy. Johnson & Johnson (JNJ) with the headlines swirling about their baby powder which was apparently found to have traces of asbestos, Boeing (BA) with a report that surfaced suggesting that they may have misled the...

“Splash Of Green” Vista Partners Daily Market Recap 10/17/19

It was a splash of green for all across the board in the markets today as it pointed to a number of better than expected earnings reports and news from across the pond that a Brexit deal may be in the works. The S&P 500 ended today's session up by 8.26 points or .28% as it closed at 2,99...

J&J Exceeds Q3 Expectations/Raises Full-Year Forecasts In the Face Of Legal Issues

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. On Tuesday, Johnson & Johnson reported their successful Q3 earnings, confirming that they h...

“Mixed At Best” Vista Partners Daily Market Recap 10/16/19

 The S&P 500 ended today's session down by 5.99 points or .2% as it closed at 2,989.69 just shy of the 3k level. The Dow lost 22.82 points closing over the 27k level at 27,001.98 down by .08%. The tech-heavy Nasdaq Composite closed above the 8k mark closing at 8,124.18 down .30% or 24...

The Dr. Susan Love Research Foundation, A “Major” Research University & Atossa Genetics (ATOS) Are Collaborating On Phase 2 Study of Intraductal Microcatheter Technology In Breast Cancer

The Dr. Susan Love Foundation for Breast Cancer Research's mission is to end breast cancer. It challenges the status quo to end breast cancer and improve the lives of people impacted by it now through education and advocacy. The Foundation drives collaborative, cutting-edge research with nontraditio...

UnitedHealth Group (UNH) Releases Its Q3 Analyst Beating Earnings Report

UnitedHealth Group Incorporated (UNH) declared its Q3 earnings report ending Sep 30th, on Tuesday exceeding analysts' expectations and raising its 2019 earnings forecast to 14.90 to $15 per share, in comparison to an earlier forecast of between $14.70 and $14.90, as per reports. UNH's revenues sa...

“A Fresh Wave Of Earnings” Vista Partners Daily Market Recap 10/15/19

Today, a wave of earnings kicked into high gear today which seemed to block out the ongoing trials and tribulations of the US-China trade war and we managed to have a very positive day in the markets. From the Dow 30, Johnson & Johnson (JNJ) reported earnings of $2.12, beating estimates ...

Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

Steven Quay received an M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over...

“Simply Red Columbus” Vista Partners Daily Market Recap 10/14/19

Today felt like a day where many were hiding or trying to hide in the US as schools, banks, and a few other companies celebrated the Columbus Day holiday but there is no rest for the wicked as the markets were open. It was lighter than normal volume day as many did play a bit of hookey and m...

Creator Of Alternative Infertility Treatments INVO Bioscience Hires NEW CEO Steven Shum

Infertility is “the inability to conceive after 12 months.” This means that a couple is not able to become pregnant after a year of trying. However, for women aged 35 and older, the inability to conceive after 6 months is generally considered infertility. According to fertilitycenter.com, the ab...

3M Acquires Acelity, Inc.

Reportedly, 3M (MMM) has completed the acquisition of Acelity, Inc., a leading global medical technology and its worldwide KCI subsidiaries for a total enterprise value of approximately $6.7 billion inclusive of debt and other adjustments. The deal was advised by Apax Partners along with controlled ...

Pfizer Shares Results Of Phase 3 Data For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

J&J Ordered To Pay Record Amount For Its Antipsychotic Drug Believed To Have Caused Gynecomastia

Reportedly, Johnson & Johnson has been asked to pay $8 billion as penalty charges to Nicholas Murray,who previously won $680,000 over his claims where J&J failed to alert young men over usage of its antipsychotic drug Risperdal causing gynecomastia, growth enlargement of male breasts, in a v...

“Optimistic Market Music” Vista Partners Daily Market Recap 10/11/19

The optimism and sweet tune or news that the US-China 'partial' trade deal was in play, imminent and apparently agreed to today fueled the market throughout as it reached mid-session highs. The Dow was up over 500 points at one point before tailing off into the close.  We should also mentio...

“Partial To Green” Vista Partners Daily Market Recap 10/10/19

The US-China trade wars were squarely in the markets' line of view again today.  An optimistic understanding flew around the "www" today that at least a partial agreement with China may be in the cards.  A meeting with President Trump and China's Vice Premier, Liu He, also had wings and th...

Walmart Launches Low-Cost Healthcare Program For Its Employees To Curb Its Healthcare Costs

The retail giant, Walmart Stores, Inc. (WMT) with 1.4 million in its collective workforce in the U.S is launching various healthcare pilot programs for its U.S employees starting January 1 in an attempt to cut healthcare costs which are a major expense for the retailer after wages, as per reports. ...

“Open…?” Vista Partners Daily Market Recap 10/9/19

All the markets apparently needed today was one word from the Chinese regarding the trade wars, "open", and the game was back on. Mind you that the Chinese only suggested that they were open to a partial deal but again the markets these days seem to hold on to what they want to here and tod...

Merck’s Two Applications For DIFICID® Drug On Review Priority List Of FDA

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the le...

“Expanding” Vista Partners Daily Market Recap 10/8/19

"Expanding" seemed to be the word of the day today. First, it was widely reported that the U.S. Commerce Department expanded its Entity List" with 28 additional Chinese firms as they had played some role in "fostering violations of human rights" against a Muslim minority in China. A Beijing...

Pfizer Presents Interim Analysis From Phase 3 Trial In Advanced BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® ...

“Trade, Cut, Confusion” Vista Partners Daily Market Recap 10/7/19

With Warner Brothers' new supervillain movie Joker experiencing an opening weekend with $247M in global ticket sales you might think all is well as headlines flew around the world today preaching its success. However, a Bloomberg article did its best to counter these good feelings with anoth...

“Fragile Wings!” Vista Partners Daily Market Recap 10/4/19

We received a good ending to a volatile week that certainly left many of our heads still spinning. As has been the custom this week the markets seem to be riding up and down on the fragile wings of each piece of economic data more than normal. Today, the economic schedule confirmed that the ...

“Rate Cut…!” Vista Partners Daily Market Recap 10/3/19

On Thursday, more economic data was released and hit the markets at 7 am pacific. The markets took an initial nosedive prior to recovering into the close after we received the ISM Non-Manufacturing Index report for September which dropped to 52.6% from the 56.4% mark in August. Layering this...

INVO Bioscience Will Exhibit At The World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26 in Barcelona

Sarasota-based INVO Bioscience, Inc.  (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the 20th World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26, 2...

INVO Bioscience Will Exhibit at American Society for Reproductive Medicine (ASRM) 2019 In Philadelphia Oct. 12-16

Sarasota-based INVO Bioscience, Inc.  (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress October 12-16, 2019 in Phi...

“Double Down?” Vista Partners Daily Market Recap 10/2/19

No sir!... I am not suggesting you double down on the stock market or anything at this point,  however, we did double our consecutive down days today as the markets got stung again & proceeded fall significantly across the board once again. The downward move came in reaction to addition...

Walgreen Collaborates With Novant Health To Expand Retail Health Care In North Carolina

Walgreen Boots Alliance (WBA), a relatively recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Reportedly, Walgreens and Novant Health, a leading healt...

“Manufacturing Woes” Vista Partners Daily Market Recap 10/1/19

Today, the markets suffered through a bit of negative economic news that came out of the manufacturing sector that seemed to surprise and bring forth woes for many on this first day of October. The Institute for Supply Management’s factory index was reported to have slipped to 47.8 in Sept...

Breast Cancer Focused Atossa (ATOS) Successfully Meets All Objectives In Phase 1 Study Today

Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have mammographic breast density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effective in...

“Q3 Positively Ends” Vista Partners Daily Market Recap 9/30/19

Today, the markets ended Q3 on a positive swing after a US Treasury representative on Saturday followed up by White House trade advisor Peter Navarro essentially refuted Friday's Bloomberg story that stated that the Trump administration is considering limits to US investors' flows into Chin...

“China Limits” Vista Partners Daily Market Recap 9/27/19

The markets ended the week on a downward slope as we continued to get less than positive news from many fronts spearheaded by the trade wars that continue to bring uncertainty and weigh on the markets this week. Bloomberg ran a story today stating that the Trump administration is considering...

“Adrift” Vista Partners Daily Market Recap 9/26/19

The markets seemed to be without a great deal of conviction and/or just adrift but lower today in a sea of headlines related to trade wars (Huawei again), tariffs, impeachment, whistleblower action more positive economic reports, and historically low jobless claims. The S&P 500 ended tod...

“New Homes Push” Vista Partners Daily Market Recap 9/25/19

After yesterday's somewhat somber "impeachment inquiry' news we started out a bit sluggish in the markets & understandably so. Then the market was given some notes from President Trump's call with Ukrainian President Zelensky and the trade wars to a bit of back seat to the new home sales...

“Somber” Vista Partners Daily Market Recap 9/24/19

It was sobering if not a somber day in the markets and throughout the US as many seemed to focus on the negative and uncertainty rather than what came about that was positive. In the economy, we learned that the Conference Board's Consumer Confidence Index for September dropped to 125.1 whi...

“Eyes On German PMI” Vista Partners Daily Market Recap 9/23/19

All eyes were on the German PMI situation on Monday as it showed that the German economy, the European union's largest economy,  had contracted in September & confirming that the manufacturing and service sectors worsened. September’s IHS Manufacturing PMI for Germany read 41.4, sign...

Merck’s Blockbuster Keytruda Plus Chemotherapy Demonstrates Improvement In Triple-Negative Breast Cancer

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at th...

“No To Montana?” Vista Partners Daily Market Recap 9/20/19

Who says no to visiting Montana this time of year? It's so beautiful & peaceful this time of year, correct? Well...the Chinese that's who.  The Chinese agricultural delegates, in fact, dared to say "no" to their previous invite and plan to visit Montana-based farms today. The markets took this ...

Fate Therapeutics (FATE) Closes Underwritten Public Offering For Proceeds of ~$173.1 million

San Diego-based Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.  The Company has established a leadership position in the clinical development and manufacture of universal...

“Ho-Hum” Vista Partners Daily Market Recap 9/19/19

After yesterday's "big decision" was revealed where the Fed met again and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%, we experienced a bit of a "ho-hum" sort of day as the markets pretty much stayed in place on relatively low volume.  The ...

“7-3 Vote” Vista Partners Daily Market Recap 9/18/19

Well, we got it, folks. Yes, the Fed met again today and voted 7-3 to raise interest rates for the second time this year by another .25 basis points to 1.75-2%. This move was as the market had widely expected. President Trump also continued to tell the Fed tht they have it all wrong stating "Jay Pow...

“Fed Up Next” Vista Partners Daily Market Recap 9/17/19

The broad markets finished higher again today, except for the Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index which moved lower by .40% or 6.31 points closing at 1,578.29. the overall positive move came about with the impending interest...

Merck’s Treatment For Rare NSCLC Gains FDA Breakthrough Therapy Designation

Reportedly, Merck KgaA’s tepotinib, a treatment for the MET exon14 skipping mutation in the genetic makeup of a lung tumor, has been awarded the U.S. Food and Drug Administration's breakthrough therapy designation. Breakthrough therapy is a United States Food and Drug Administration designatio...

Atossa Genetics Completes Enrollment, Dosing & Expects to Report Preliminary Results For Phase 1 Study Of Oral Endoxifin in Next 30 Days

It is estimated that approximately ten million women in the United States have MBD, for which there is no FDA-approved treatment. Although oral tamoxifen is approved to prevent breast cancer in “high-risk” women, it is used by less than 5 percent of women with an increased risk of developing...

Amgen Gears Up To Own Worldwide Rights Of Otezla®

Reportedly, Amgen (AMGN) has entered in an agreement with Celgene Corporation (CELG) to acquire the worldwide rights of the only oral, a non-biologic treatment for psoriasis and psoriatic arthritis, Otezla. The acquisition is set to proceed for an amount of $13.4 billion in cash, or approximate...

Record Q2 Announced By Fertility Med Device Firm INVO Bioscience- (Increase of 498%)

Sarasota, FL-based INVO Bioscience, Inc. (IVOB), a medical device company that was granted FDA clearance for its Intravaginal Culture System, INVOcell®, released its financial results for Q2 2019. The INVO Procedure is a new and effective fertility treatment option allowing fertilization and...

Seattle’s Atossa Genetics (ATOS) Published Q2 Financial Results & Company Update

Seattle-based Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today published their financial results for Q2, 2019 and provided an update on recent company developments....

Atossa Genetics CEO Steven Quay Gives Tedx Talk Regarding Relationship of Dense Breast Tissue & Breast Cancer Risk

Steven Quay is the founder of Seattle-based Atossa Genetics, Inc., dedicated to breast cancer prevention. He received a Ph.D. in Biological Chemistry and a M.D. from the University of Michigan, a postdoc at MIT and Harvard, and he was a faculty member at Stanford Medical School. His contribution...

Pfizer Spinning Combined Off-Patent Drug Business With Generic Drugmaker Mylan NV

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer annonced that it will combinen off-Patent Drug Business, Upjohn, with generic drugmaker Mylan NV. This combination will surfacd on t...

Walgreen Growing Kaleo Partnership Amid National Shortage Of Allergy Shots

Walgreen Boots Alliance (WBA), a recent addition to the Dow 30, is a pharmacy-led, health and wellbeing enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. Last week, Walgreens Boots Alliance Inc announced that it is ex...

J&J Continuing Research For Mid-Stage HIV Vaccine

As per reports, Johnson & Johnson (JNJ) is staged to move forward with a late-stage study of an investigational vaccine for Human Immunodeficiency Virus (HIV), a condition that weakens the immune system of the body in countries like America and Europe. The company is continuing its research...

Microsoft Partnering With Providence St. Joseph Health To Move to the Cloud

Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses, supports and sells computer software, consumer electronics, personal computers, and related services. Recently, Providence St. Joseph Health and Microsoft reportedly entered ...

MARK THESE DATES ALERT: Biohaven Pharmaceutical Holding Company (BHVN) July 11-14, 2019

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectu...

Pfizer Presented Data On Duchenne Muscular Dystrophy (DMD) In Florida

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc introduced the initial Phase 1b clinical data on PF-06939926 at 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference...

Atossa Genetics Reports Preliminary Analysis From Phase 2 – “Proprietary Topical Endoxifen Significantly Reduced Breast Density”

Legislation has been recently enacted in approximately 35 states requiring that women be notified if they have Mammographic Breast Density (MBD) and those notifications typically state that women with MBD have a higher risk of developing breast cancer, and that mammography may not be as effect...

Pfizer To Acquire Array BioPharma Seeking to Strengthen Its Innovative Biopharmaceutical Business

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. This week, Pfizer Inc announced to acquire Array BioPharma Inc in a definitive merger agreement. Array BioPharma Inc, a biopharmaceutical company ...

Low-Cost Fertility Treatment Firm INVO Bioscience Hires Former Cooper Surgical Executive

On a worldwide basis, there are approximately 150 million infertile couples. Approximately 1.5 million IVF cycles are performed annually corresponding to approximately 1% of the infertile couples worldwide. Including IUI (another 1% worldwide), this represents an approximate $6.6 billion worldwi...

Antisense Focused Stoke Therapeutics’ IPO Is Off To A Great Start Today!

Bedford, Massachusetts-based Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. They develop antisense oligonucleotide medicines that increase gene expression to treat genetic epile...

Exciting FDA Approval Gained For Merck’s Keytruda in Treatment of Head & Neck Cancer

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at th...

Merck Announces The Acquisition Of TGFβ Focused Tilos Therapeutics

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be a...

INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director Michael Dinkins

One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.06/share & a low of $2.895/share today and closed the day at $2.93/share down 4.56% on...

Oklahoma Attorney General Mike Hunter Files Multibillion-dollar “Opioid” Case Against J&J

Reportedly Johnson & Johnson (JNJ) has been accused of using deceitful methods to encourage the over-use of opioid painkillers that has led to a U.S. opioid epidemic. Mike Hunter, Oklahoma Attorney General recently filed a  multi-billion dollar case demanding J&J to pay for helping cau...

Travelers Now Targeting Medical Tech, Pharmaceuticals & Digital Health Firms With Life Sciences Offering

Recently, The Travelers Companies, Inc. (TRV) was reported to have introduced a complete Life Sciences practice offering insurance and risk management solution in pharmaceuticals, digital health and medical devices including health care IT, medical software, and telemedicine. Their program is ...

FDA Approves Novartis AG’s PI3K Inhibitor Treatment For Advanced Breast Cancer In Men & Women

According to multiple reports on Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s PI3K inhibitor treatment,  a drug called alpelisib, which will be marketed under the brand name Piqray. Piqray is approved to be administered in combination with hormone therapy for post...

Merck Acquiring Peloton Therapeutics Pushing to Diversify Offerings In Cancer

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at ...

INSIDER BUYING ALERT: Community Health Systems, Inc. (CYH) Director James S. Ely III

One of the largest publicly traded hospital companies in the US and a leading operator of acute care hospitals in communities across the country, Community Health Systems, Inc (CYH) hit an intraday high of $3.29/share & a low of $3.115 today and closed the day at $3.28 up nicely 3.14% on 1.23 m...

Seattle’s Atossa Provides Q1 Results & Progress Developments

Seattle based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. On Monday after the market close Atossa announced their financial results for the quarter ended Ma...

Australian Competition and Consumer Commission Pushes Forward GSK-Pfizer Consumer Healthcare Business

The GlaxoSmithKline' deal seeking to purchase & combine Pfizer's consumer healthcare business  with their own has recently received approval from Australia’s antitrust regulator recently  called the Australian Competition and Consumer Commission (ACCC.)  It was reported that the ACCC anti...

UnitedHealth Group Initiates “Low Cost” Maternity Care Programs

Increasing healthcare costs has become a major concern in the United States especially when it comes to maternity costs from prenatal to postpartum care which has been surging. Now UnitedHealth Group Incorporated (UNH) has come up with a health care plan to cut maternity cost where partner hospita...

Pfizer’s Drug For Treating Fatal Heart Disease Gains FDA Approval

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Pfizer Inc.'s oral drug tafamidis effective in treating “transthyretin amyloid cardiomyopathy”, a rare and fatal heart disease recently gained appr...

United Healthcare Received $4.5M Funded 5-year Accountable Health Communities Award In Hawaii

United Healthcare recently received a $4.5 million funded 5-year Accountable Health Communities award from the Centers for Medicare & Medicaid Services (CMS) to improve social related health services in Oahu, Hawaii. The program seeks to partner with Waianae Coast Comprehensive Health Center, ...

“A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy”

Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced this week that Steven C. Quay, M.D., Ph.D., Atossa’s President, and CEO, provided an update on the Company...

Hope For Restoring Young Cancer Patient’s Fertility Emerges After New Research

Researchers with the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute, have successfully restored fertility to non-human primate model of childhood cancer, creating hope that the same process may be successful in humans. The researchers were able to cryopreserve ...

FDA Approves Johnson & Johnson’s Advanced Bladder Cancer Drug

According to The American Cancer Society’s website estimates for bladder cancer in the United States for 2019 are about 80,470 new cases of bladder cancer (about 61,700 in men and 18,770 in women and about 17,670 deaths from bladder cancer (about 12,870 in men and 4,800 in women. The rates of n...

UnitedHealthcare Widens Collaboration With Care Providers In More Than 30 States

Dow 30 component UnitedHealth Group  Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company's UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employ...

Walgreens & VillageMD Integrating Adult Primary Health Care & Pharmacy Offering In Houston

Leading Primary health care provider VillageMD and Walgreen announced that they are coming together to offer valuable primary health care services under the brand “Village Medical at Walgreens” to adult patients within the Houston community.  Initially, VillageMD is to set up health care clin...

Breast Cancer Treatment Innovator Atossa Genetics Announced Year End 2018 Financial Results & Provided Business Update This Week

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. Today Atossa announced year-end 2018 financial results and provided an update on recent company de...

Institutional Review Board Approves Use of Atossa’s Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS) ("Atossa") is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  Shares of Atossa jumped to a high of $4.865 today and are currently trading at $4.14 u...

Breast Cancer Treatment Focused Biotech Atossa Genetics (NASDAQ: ATOS) Raises $10 Million – Jumps Again!

Atossa Genetics (ATOS) a Seattle-based biotech firm focused on developing treatments for breast cancer had another wonderful day as it jumped up 24.47% closing at $4.40 on 24.84 Million shares of trading. This increase came about today as ATOS announced that on March 14th and 15th, 2019, it rece...

MARKET ALERT: Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...

INVO Bioscience Partners with “Egg Whisperer” To Launch San Francisco Bay Area Embryology Center

MEDFORD, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experi...

Developer o​f Programmed Cellular Immunotherapies Fate Therapeutics (NASDAQ: FATE) Reports Q4 & Full Year 2018 Financial Results – Highlights Operational Progress

San Diego-based Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31...

American Society of Breast Surgeons Now Recommends Genetic Testing for All Breast Cancer Patients

The American Society of Breast Surgeons released new recommendations last Thursday that suggested genetic testing for inherited mutations should be offered to all breast cancer patients. These recommendations are in somewhat of opposition with those offered by the National Comprehensive Cancer Ne...

MARKET ALERT: Atossa Updates Status of Pre-menopausal, Estrogen-receptor Positive Breast Cancer Patient

Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical tri...

Fertility Treatment Innovator INVO Bioscience Adds Michael J. Campbell as COO/VP of Business Development

Medford, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation tha...

Breast Cancer Treatment Innovator Atossa Genetics’ CEO Issues Annual Letter to Shareholders Highlighting Strategy for 2019

Seattle-based Atossa Genetics Inc. (ATOS) a  clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions issued the following letter from Dr. Steven C. Quay, President, and CEO, to Atossa shareholders:    ...

INVO Bioscience & Ferring Pharmaceuticals Close Exclusive U.S. Licensing Agreement to Commercialize INVOcell™ For Treatment of Infertility

INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology & is a revolutionary in vivo method of vaginal incubation that offers patients a more natural a...

Lilly Paying $8 Billion for Loxo Oncology During JPM2019

JPMorgan Healthcare Conference week brings forth another sizable deal as Lilly (LLY) will commence a tender offer to acquire all outstanding shares of Loxo Oncology (LOXO) for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. Lilly is reported to be making a bet on a ...

Largest Pharmaceutical Deal Ever to Take Place Between Bristol-Myers and Celgene

In the biggest pharmaceutical deal ever, Bristol-Myers Squibb will buy Celgene for $74 billion, combining two the largest cancer drug businesses in the world. Wall Street analysts have questioned whether this merge would solve the individual challenges the two companies face. The companies have st...

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us